Protective effect of soy isoflavones and activity levels of plasma paraoxonase and arylesterase in the experimental nonalcoholic steatohepatitis model

Digestive Diseases and Sciences

Volumn 52, Issue 8, 2007, Pages 2006-2014

  Ustundag, Bilal ^a   Bahcecioglu, Ibrahim Halil ^b   Sahin, Kazim ^a   Duzgun, Sevda ^a   Koca, Suleyman ^a   Gulcu, Funda ^a   Ozercan, Ibrahim Hanifi ^a  

^a FIRAT UNIVERSITY   (Turkey)

^b Thoracic Surgery Department   (Turkey)

Author keywords

Arylesterase; Methionine and choline deficient diet; Nonalcoholic steatohepatitis; Paraoxonase; Soy isoflavone

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; CHOLESTEROL; CHOLINE; ISOFLAVONE DERIVATIVE; MALONALDEHYDE; METHIONINE; SOY ISOFLAVONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FIBROSIS; HISTOPATHOLOGY; INFLAMMATION; LIPID PEROXIDATION; LIVER; MALE; NECROSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CHOLINE DEFICIENCY; DISEASE MODELS, ANIMAL; FATTY LIVER; HEPATITIS; ISOFLAVONES; LIPID PEROXIDATION; LIVER; MALE; MALONDIALDEHYDE; METHIONINE; RATS; SOYBEANS;

EID: 34347395156     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9251-9     Document Type: Article

References (45)

1. Diehl AM (1999) Nonalcoholic steatohepatitis. Semin Liver Dis 19(2):221-229
2. Koteish A, Mae Diehl A (2002) Animal models of steatohepatitis. Best Pract Res Clin Gastroenterol 16(5):679-690
3. Chitturi S, Farrell GC (2001) Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 21(1):27-41
4. 2 generation in liver mitochondria. Carcinogenesis 21(5):983-989
5. Diehl AM (2000) Cytokine regulation of liver injury and repair. Immunol Rev 174:160-171
6. Hruszkewycz AM (1998) Evidence for mitochondrial DNA dmage by lipid peroxidation. Biochem Biophys Res Commun 153:191-197
7. Parola M, Pinzani M, Casini A, Albano E, Poli G, Gentilini A, Gentilini P, Dianzani MU (1993) Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen alpha 1 (I) gene expression in human liver fat-storing cells. Biochem Biophys Res Commun 194:1044-1050
8. George J, Pera N, Phung N, Leclercq I, Yun Hou J, Farrell G (2003) Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol 39:756-764
9. Kirsch R, Clarkson V, Shephard EG, Marais DA, Jaffer MA, Woodburne VE, Kirsch RE, de Hall PL (2003) Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J Gastroenterol Hepatol 18:1272-1282
10. Martucci CP, Fishman J (1993) P450 enzymes of estrogen metabolism. Pharmacol Ther 57(2-3):237-257
11. Kulling SE, Lehmann L, Metzler M (2002) Oxidative metabolism and genotoxic potential of major isoflavone phytoestrogens. J Chromotogr 777:211-218
12. Anila L, Vijayalakshmi NR (2003) Antioxidant action of flavonoids from Mangifera indica and Emblica officinialis in hypercholesterolmic rats. Food Chem 83:569-574
13. Choi C, Hyeyeon C, Park J, Song Y (2003) Supressive effects of genistein on oxidative stres and NF kB activation in RAW 264.7 macrophages. Biosci Biotechnol Biochem 67(9)1916-1922
14. Rice Evans CA, Miller NJ, Bolwell PG, Bramley PM, Pridham JB (1995) The relative antioxidant activities of plant derived polyphenolic flavonoids. Free Radical Res 22:375-383
15. Abad MJ, Bermejo P, Willar A (1995) The activity of flavonoids extracted from Tnacetum microphylumm DC (Compositae) on soybean lipoxygenase and prostaglandin synthetase. Gen Pharmacol 26:815-819
16. Robak J, Gryglewsky RJ (1996) Bioactivity of flavonoids. Polish J Pharmacol Pharm 48:555-564
17. Wiseman H, O'Reilly JD, Adlercreutz H, Mallet AI, Bowey EA, Rowlland IR, Sanders TA (2000) Isoflavone phytoestrogens consumed in soy decrease F (2)-isoprostane concentrations and increase resistance of low-density lipoprotein to oxidation in humans. Am J Clin Nutr 72(2):395-400
18. Djuric Z, Chen G, Doerge DR, Heilbrun LK, Kucuk O (2001) Effect of soy isoflavone supplementation on markers of oxidative stress in men and women. Cancer Lett 22(1):1-6
19. Demonty I, Lamrche B, Deshaies Y, Jacques H (2002) Role of soty isoflavones in the hypotrigliseridemic effect of soy protein in the rat. J Nutr Biochem 13:671-677
20. Beynen AC (1990) Mode of cholesteremic action of dieatary proteins. Monogr Atheroscler 16:153-159
21. Sanchez A, Hubbard RW (1991) Plasma amino acids and the insulin glucagon ratio as a explanation for the dietary protein modulation of atherosclerosis. Med Hypothesis 36:27-32
22. Forsyhte WA (1990) Dietary protein, cholesterol and thyroxine: a proposed mechanism. J Clin Nutr 68(Suppl):S101-S104
23. Potter SM (1998) Soy protein and cardiovascular disease: the impact of bioactive components in soy. Nutr Rev 56:231-235
24. Rinella ME, Green RM (2004) The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 40(1):47-51
25. Yagi K (1984) Assay for blood plasma and serum. Methods Enzmol 105:328-331
26. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipide eproxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351-358
27. Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P (1995) Gln-Arg 192 polymorphysm of paraoxonase and coronary heart disease in y-type 2 diabetes. Lancet 346:869-872
28. Juretic D, Tadjanovic M, Rekic B, Simeon Rudolf V, Reiner E, Barlicic M (2001) Serum paraoxonase actiivities in hemodialyzed uremic patients. Cohort study Croat Med J 42:146-150
29. Brunt E, Janney C, Bisceglie A, Neuschwander-Tetri BA, Bacon BR (1999) Nonalcoholic steatohepatitis; a proposal for grading and staging the histopathologic lesions. Am J Gastroenterol 94:2467-2474
30. Bahcecioglu IH, Yalniz M, Ataseven H, Bulbuller N, Kececi M, Demirdag K, Ozercan I, Ustundag B (2004) TNF-alpha and leptin in experimental liver fibrosis models induced by carbon tetrachloride and by common bile duct ligation. Cell Biochem Funct 22(6):359-363
31. Kirsch R, Clarkson V, Shephard EG, Marais DA, Jaffer MA, Woodburne VE, Kirsch RE, Hall PL (2003) Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J Gastroenterol Hepatol 18(11):1272-1282
32. Fort J, Oberti F, Pilette C, Veal N, Gallois Y, Douay O, Rousselet MC, Rosenbaum J, Cales P (1998) Antifibrotic and hemodynamic effects of the early and chronic administration of octreotide in two models of liver fibrosis in rats. Hepatology 28(6):1525-1531
33. Harrison SA, Kadakia S, Lang K, Schenker S (2002) Nonalcoholic steatohepatitis: What we know in the new millenium. Am J Gastroenterol 97:2714-2724
34. Lee RG (1989) Nonalcoholic steatohepatitis: A study of 39 patients. Hum Pathol 20:594-598
35. Day C, James O (1998) Steatohepatitis: A tale of two "hits"? Gastroenterology 114:842-845
36. Lieber CS (1997) Role of oxidative stres and antioxidant therapy in alcoholic and nonalcholic liver disease. Adv Pharmacol 38:601-628
37. Aviram M (1996) Interaction of oxidized low density lipoproteins and increased atherogenicty of antioxidants. Eur J Clin Chem Clin Biochem 34:599
38. Zhishen J, Mengencheng T, Jianmibg W (1999) The determination of flavonoid contents in mulberry and their scavenging effects on superoxide radicals. Food Chem 64:555-559
39. Gryglewski RJ, Korbut R, Robak J, Swies J (1987) On the mechanism of antithrombotic action of flavonoids. Biochem Pharmacol 36(3):317-322
40. Lee MK, Bok SH, Jeong TS, Moon SS, Lee SE, Park YB, Choi MS (2002) Supplementation of Naringenin and its synthetic derivative alters antioxidant enzyme activities of erythrocyte and liver in high cholesterol fed rats. Biorg Med Chem 10:2239-2244
41. Seo HJ, Jeong KS, Lee MK, Park YB, Jung UJ, Kim HJ, Choi MS (2003) Role of naringenin suplement in regulation of lipid and ethanol metabolism in rats. Life Sci 73:933-946
42. Fuhrman B, Aviram M (2001) Flavonoids protect LDL from oxidation and attenuate atherosclerosis. Curr Opin Lipidol 12(1):41-48
43. Beltowski J, Wojcicka G, Jamroz A (2003) Leptin decreases plasma paroxonase 1 activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atheroclerosis 170:21-29
44. Beltowski J, Wojcica G, Mydlardrczyk M, Jamroz A (2002) The effect of peroxisome prolifarator activated receptors alpha (PPAR a) agonist fenofibrate on lipid peroxidation, total antioxidant capacity and plasma paraoxonase 1 (PON1) activity. J Physiol Pharmacol 53:463-475
45. Starkel P, Sempoux C, Leclercq I, Herin M, Deby C, Desager JP, Horsmans Y (2003) Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. J Hepatol 39(4):538-546